Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2002
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity
Diederik F S Kehrer, Annelies M Bos, Jaap Verweij, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 6, 2019
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i>-mutated, high-grade ovarian cancer, and an update on safety
Rebecca S Kristeleit, Ana Oaknin, Isabelle Ray-Coquard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group
Graham G Dark, A Hilary Calvert, Robert Grimshaw, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 9, 2021
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
Andrew R Clamp, Domenica Lorusso, Amit M Oza, et al.
The Lancet. Oncology
|
May 4, 2020
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Cancer Medicine
|
September 22, 2021
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety
Ana Oaknin, Amit M Oza, Domenica Lorusso, et al.
Gynecologic Oncology
|
August 31, 2020
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma
Nicoletta Colombo, Amit M Oza, Domenica Lorusso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2020
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma
Amit M Oza, Domenica Lorusso, Carol Aghajanian, et al.
Lancet (London, England)
|
September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L Coleman, Amit M Oza, Domenica Lorusso, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 1, 2002
Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity
Diederik F S Kehrer, Annelies M Bos, Jaap Verweij, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
November 6, 2019
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, <i>BRCA</i>-mutated, high-grade ovarian cancer, and an update on safety
Rebecca S Kristeleit, Ana Oaknin, Isabelle Ray-Coquard, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 9, 2005
Randomized trial of two intravenous schedules of the topoisomerase I inhibitor liposomal lurtotecan in women with relapsed epithelial ovarian cancer: a trial of the national cancer institute of Canada clinical trials group
Graham G Dark, A Hilary Calvert, Robert Grimshaw, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 9, 2021
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
Andrew R Clamp, Domenica Lorusso, Amit M Oza, et al.
The Lancet. Oncology
|
May 4, 2020
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial
Jonathan A Ledermann, Amit M Oza, Domenica Lorusso, et al.
Cancer Medicine
|
September 22, 2021
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety
Ana Oaknin, Amit M Oza, Domenica Lorusso, et al.
Gynecologic Oncology
|
August 31, 2020
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma
Nicoletta Colombo, Amit M Oza, Domenica Lorusso, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 26, 2020
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma
Amit M Oza, Domenica Lorusso, Carol Aghajanian, et al.
Lancet (London, England)
|
September 17, 2017
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert L Coleman, Amit M Oza, Domenica Lorusso, et al.
Page
of 2